Pharvaris FY2029 Earnings Forecast Cut by HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at HC Wainwright dropped their FY2029 earnings estimates for Pharvaris in a research note issued on Tuesday, October 6th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $2.88 for the year, down from their prior forecast of $3.09. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Pharvaris’ FY2030 earnings at $6.62 EPS.

PHVS has been the subject of several other reports. Citizens Jmp upped their price objective on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research report on Wednesday, September 9th. Guggenheim lifted their target price on Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. UBS Group set a $60.00 target price on Pharvaris in a research note on Tuesday. Rosenblatt Securities set a $60.00 price target on Pharvaris in a research report on Wednesday, September 9th. Finally, Leerink Partners raised their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $58.60.

Pharvaris Trading Down 1.8%

PHVS stock opened at $31.12 on Wednesday. The stock has a 50-day moving average price of $34.85 and a two-hundred day moving average price of $32.33. Pharvaris has a 1 year low of $20.65 and a 1 year high of $43.25. The stock has a market cap of $2.04 billion, a PE ratio of -10.20 and a beta of -2.46.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06).

Insider Transactions at Pharvaris

In other news, Director Elisabeth Bjork sold 52,500 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the sale, the director owned 15,167 shares in the company, valued at $574,677.63. This represents a 77.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, President Peng Lu sold 100,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the sale, the president directly owned 64,953 shares of the company’s stock, valued at approximately $2,273,355. The trade was a 60.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 513,102 shares of company stock valued at $18,643,666. 11.84% of the stock is owned by insiders.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently added to or reduced their stakes in the company. venBio Partners LLC bought a new stake in Pharvaris during the second quarter worth $160,569,809. Wellington Management Group LLP lifted its stake in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after acquiring an additional 274,034 shares during the last quarter. Commodore Capital LP grew its position in shares of Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares during the period. 5AM Venture Management LLC bought a new position in shares of Pharvaris in the 2nd quarter valued at about $27,581,008. Finally, Seven Fleet Capital Management LP increased its stake in shares of Pharvaris by 144.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after purchasing an additional 457,804 shares during the last quarter.

About Pharvaris

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.